Read by QxMD icon Read

Mri and prostate biopsy

Janet Fallon, Martin Plummeridge, Richard Daly, Andrew Medford
We report a case of a 68-year-old gentleman, found to have a right hilar soft tissue mass whilst undergoing CT staging for prostate cancer. MRI imaging showed a heterogenous, enhancing solid mass without evidence of fat content. A linear probe endobronchial ultrasound-guided transbronchial needle aspiration was performed using a 19G needle. This confirmed the diagnosis of a benign chondroid hamartoma, avoiding the need for more invasive surgical biopsy.
February 7, 2018: Monaldi Archives for Chest Disease, Archivio Monaldi Per le Malattie del Torace
Ping Li, Sungyong You, Christopher Nguyen, Yanping Wang, Jayoung Kim, Deepika Sirohi, Asha Ziembiec, Daniel Luthringer, Shih-Chieh Lin, Timothy Daskivich, Jonathan Wu, Michael R Freeman, Rola Saouaf, Debiao Li, Hyung L Kim
MRI is used to image prostate cancer and target tumors for biopsy or therapeutic ablation. The objective was to understand the biology of tumors not visible on MRI that may go undiagnosed and untreated. Methods: Prostate cancers visible or invisible on multiparametric MRI were macrodissected and examined by RNAseq. Differentially expressed genes (DEGs) based on MRI visibility status were cross-referenced with publicly available gene expression databases to identify genes associated with disease progression...
2018: Theranostics
Veeru Kasivisvanathan, Antti S Rannikko, Marcelo Borghi, Valeria Panebianco, Lance A Mynderse, Markku H Vaarala, Alberto Briganti, Lars Budäus, Giles Hellawell, Richard G Hindley, Monique J Roobol, Scott Eggener, Maneesh Ghei, Arnauld Villers, Franck Bladou, Geert M Villeirs, Jaspal Virdi, Silvan Boxler, Grégoire Robert, Paras B Singh, Wulphert Venderink, Boris A Hadaschik, Alain Ruffion, Jim C Hu, Daniel Margolis, Sébastien Crouzet, Laurence Klotz, Samir S Taneja, Peter Pinto, Inderbir Gill, Clare Allen, Francesco Giganti, Alex Freeman, Stephen Morris, Shonit Punwani, Norman R Williams, Chris Brew-Graves, Jonathan Deeks, Yemisi Takwoingi, Mark Emberton, Caroline M Moore
Background Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited. Methods In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostate cancer who had not undergone biopsy previously to undergo MRI, with or without targeted biopsy, or standard transrectal ultrasonography-guided biopsy...
March 18, 2018: New England Journal of Medicine
Eric J Jordan, Charles Fiske, Ronald Zagoria, Antonio C Westphalen
PURPOSE: To determine the diagnostic accuracy of ADC values in combination with PI-RADS v2 for the diagnosis of clinically significant prostate cancer (CS-PCa) compared to PI-RADS v2 alone. MATERIALS AND METHODS: This retrospective study included 155 men whom underwent 3-Tesla prostate MRI and subsequent MR/US fusion biopsies at a single non-academic center from 11/2014 to 3/2016. All scans were performed with a surface coil and included T2, diffusion-weighted, and dynamic contrast-enhanced sequences...
March 17, 2018: Abdominal Radiology
Wan Song, Seok Hwan Bang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, Chan Kyo Kim, Hyun Moo Lee
INTRODUCTION: The objective of this study was to investigate the effect of Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) on prediction of postoperative Gleason score (GS) upgrading for patients with biopsy GS 6 prostate cancer. PATIENTS AND METHODS: We retrospectively reviewed 443 patients who underwent magnetic resonance imaging (MRI) and radical prostatectomy for biopsy-proven GS 6 prostate cancer between January 2011 and December 2013. Preoperative clinical variables and pathologic GS were examined, and all MRI findings were assessed with PI-RADSv2...
February 23, 2018: Clinical Genitourinary Cancer
Virendra Kumar, Girdhar S Bora, Rajeev Kumar, Naranamangalam R Jagannathan
Prostate cancer (PCa) is one of the most prevalent cancers in men. A large number of men are detected with PCa; however, the clinical behavior ranges from low-grade indolent tumors that never develop into a clinically significant disease to aggressive, invasive tumors that may rapidly progress to metastatic disease. The challenges in clinical management of PCa are at levels of screening, diagnosis, treatment, and follow-up after treatment. Magnetic resonance imaging (MRI) methods have shown a potential role in detection, localization, staging, assessment of aggressiveness, targeting biopsies, etc...
April 2018: Progress in Nuclear Magnetic Resonance Spectroscopy
Dennis Robins, Michael Lipsky, Arindam RoyChoudry, Sven Wenske
OBJECTIVE: To investigate patient pain perception from receiving MRI fusion guided prostate biopsy (FBx) in addition to transrectal ultrasound guided template biopsy (TBx) versus pain from standard TBx alone. MATERIALS AND METHODS: Patients undergoing FBx+TBx or TBx alone from April 2016 through February 2017 completed a validated pain survey after biopsy. Responses were graded from 0-10 (0: no pain/willing to return for repeat procedure; 10: excruciating pain/not willing to return for repeat procedure if necessary)...
March 12, 2018: Urology
Sunao Shoji, Akio Hashimoto, Tomoya Nakamura, Shinichiro Hiraiwa, Haruhiro Sato, Yoshinobu Sato, Takuma Tajiri, Akira Miyajima
The present study evaluated three-dimensional shear wave elastography (3D SWE) in the detection of clinically significant prostate cancer. Clinically significant prostate cancer was defined by a minimum of one biopsy core with a Gleason score of 3+4 or 6 with a maximum cancer core length >4 mm. Patients with serum prostate-specific antigen levels of 4.0-20.0 ng/ml who were suspected of having prostate cancer from multi-parametric magnetic resonance imaging (mpMRI) were prospectively recruited. The 3D SWE was performed pre-biopsy, after which patients underwent MRI-transrectal ultrasound image-guided targeted biopsies for cancer-suspicious lesions and 12-core systematic biopsies...
April 2018: Biomedical Reports
Juha Knaapila, Heini Kallio, Antti J Hakanen, Kari Syvänen, Otto Ettala, Esa Kähkönen, Tarja Lamminen, Marjo Seppänen, Ivan Jambor, Antti Rannikko, Jarno Riikonen, Eveliina Munukka, Erkki Eerola, Marianne Gunell, Peter J Boström
OBJECTIVES: To determine, in a prospective, multicenter setting, the prevalence of fluoroquinolone (FQ) resistant and extended spectrum beta lactamase (ESBL) producing E. coli strains in men undergoing transrectal ultrasound guided prostate biopsy (TRUS-Bx) in Finland and to survey the associated risk factors for having the previously mentioned strains. MATERIALS AND METHODS: This is a substudy of the trial investigating the role of magnetic resonance imaging (MRI) in prostate cancer diagnosis (multi-IMPROD, NCT02241122)...
March 13, 2018: BJU International
Jennifer B Gordetsky, Benjamin Saylor, Sejong Bae, Jeffrey W Nix, Soroush Rais-Bahrami
OBJECTIVES: To assess management choices in patients who undergo magnetic resonance imaging (MRI)/ultrasound (MRI/US) fusion-guided prostate biopsy compared to patients who undergo systematic biopsy. METHODS: We compared men who underwent MRI/US fusion-guided prostate biopsy to those who underwent systematic 12-core biopsy from 2014 to 2016. Patient demographics and pathologic findings were reviewed. The highest grade group per case was considered for analysis. RESULTS: Follow-up was available on 133 patients who underwent MRI/US targeted biopsy and 215 patients who underwent systematic biopsy...
March 8, 2018: Urologic Oncology
Juan Gómez Rivas, Francesco Giganti, Mario Álvarez-Maestro, María Jose Freire, Veeru Kasivisvanathan, Luis Martinez-Piñero, Mark Emberton
CONTEXT: The indeterminate multiparametric prostate magnetic resonance image (mpMRI) lesion is one which cannot be classified as "positive" or "negative" for suspected cancer. Currently, there is no consensus on how to manage patients with indeterminate mpMRIs where areas cannot be classified as positives or negatives (Prostate Imaging Reporting and Data System [PI-RADS] 3 or Likert 3). OBJECTIVE: To define the concept of indeterminate lesion and describe the management strategies that may be adopted for these patients...
March 7, 2018: European Urology Focus
Amirali Salmasi, Jonathan Said, Alan W Shindel, Pooria Khoshnoodi, Ely R Felker, Anthony E Sisk, Tristan Grogan, Debbie McCullough, John Bennett, Helen Bailey, H Jeffrey Lawrence, David A Elashoff, Leonard S Marks, Steven S Raman, Phillip G Febbo, Robert E Reiter
PURPOSE: Multiparametric MRI (mpMRI) and biopsy-based molecular tests such as the 17-gene Oncotype DX® Genomic Prostate Score™ (GPS) assay are increasingly used to improve risk stratification in men with clinically localized prostate cancer (PCa). The GPS assay was previously shown to be a significant independent predictor of adverse pathology (AP) at radical prostatectomy (RP) in men diagnosed with systematic biopsies only. We therefore investigated the ability of GPS to predict AP in the setting of MRI-guided prostate biopsy...
March 7, 2018: Journal of Urology
Neal Patel, Joshua A Halpern, Khushabu Kasabwala, Eliza Cricco-Lizza, Michael Herman, Daniel Margolis, Chris Xu, Brian D Robinson, Yi Wang, Timothy Mcclure, Jim C Hu
PURPOSE: To determine the association between multiple regions of interest (ROI) on pre-biopsy magnetic resonance imaging (MRI) and the detection of clinically significant prostate cancer (CSPC) in men undergoing MRI ultrasound fusion biopsy (Fbx). METHODS: We performed a retrospective, single-institution analysis of men who underwent fusion biopsy. Men with prior positive biopsies, MRIs performed at outside institutions and MRIs prior to release of Prostate Imaging Reporting and Data System (PI-RADS) version 2 were excluded, resulting in 381 subjects...
March 5, 2018: Journal of Urology
Anna Luzurier, Paul-Hugo Jouve De Guibert, Alexandre Allera, Sarah F Feldman, Pierre Conort, Jean Marc Simon, Pierre Mozer, Eva Compérat, Franck Boudghene, Vincent Servois, Olivier Lucidarme, Benjamin Granger, Raphaele Renard-Penna
BACKGROUND: The incremental value of dynamic contrast-enhanced (DCE) imaging in localizing radiorecurrent prostate cancer is uncertain. PURPOSE: To assess the added-value of DCE imaging to the combination T2 -weighted imaging (T2 W)+diffusion-weighted imaging (DWI) in detecting locally radiorecurrent prostate cancer (PCa), by radiologists with different levels of experience. STUDY TYPE: Analytic retrospective study. POPULATION: In all, 52 men with biological suspected PCa recurrence after radiotherapy were retrospectively included...
March 8, 2018: Journal of Magnetic Resonance Imaging: JMRI
Pierre Graff, Daniel Portalez, Amélie Lusque, Thomas Brun, Richard Aziza, Jonathan Khalifa, Mathieu Roumiguié, Marie-Laure Quintyn Ranty, Thomas Filleron, Jean-Marc Bachaud, Bernard Malavaud
PURPOSE: Focal therapy of prostate cancer requires precise positioning of therapeutic agents within well-characterized index tumors (ITs). We assessed the feasibility of low-dose-rate ultrafocal brachytherapy. METHODS AND MATERIALS: The present study was an institutional review board-approved European Clinical Trials Database-registered phase II protocol. Patients referred (October 2013 to August 2016) for active surveillance (prostate-specific antigen <10 ng/mL, cT1c-cT2a, Gleason score on referring biopsy specimens ≤6 (3+3), ≤3 positive biopsy cores, ≤50% of cancer) were preselected...
February 2, 2018: International Journal of Radiation Oncology, Biology, Physics
Stig Müller, Gunder Lilleaasen, Tor Erik Sand, Lars Løfsgaard, Manuela Estop-Garanto, Dan Helgø, Peter Sund, Vegard Mygland
PURPOSE: Since January 2015, all men referred to urologists in Norway due to elevated PSA or other suspicion of prostate cancer underwent multiparametric MRI (mpMRI) before prostate biopsy. At our hospital, patients and the initial MRI were assessed by an urologist and if deemed necessary, patients were referred to another institution for MR/US fusion biopsies. Before MR/US biopsy, patients underwent a second mpMRI. Since we noticed disagreement of these two mpMRIs before biopsy, we retrospectively assessed the level of agreement between the two mpMRIs from the two institutions...
March 5, 2018: World Journal of Urology
Hiram Shaish, Whitney Feltus, Jonathan Steinman, Elizabeth Hecht, Sven Wenske, Firas Ahmed
PURPOSE: The aim of this study was to assess the impact of a structured reporting template on adherence to the Prostate Imaging Reporting and Data System (PI-RADS) version 2 lexicon and on the diagnostic performance of prostate MRI to detect clinically significant prostate cancer (CS-PCa). METHODS: An imaging database was searched for consecutive patients who underwent prostate MRI followed by MRI-ultrasound fusion biopsy from October 2015 through October 2017. The initial MRI reporting template used included only subheadings...
March 2, 2018: Journal of the American College of Radiology: JACR
Raisa S Pompe, Bieke Kühn-Thomä, Yamini Nagaraj, Valia Veleva, Felix Preisser, Sami-Ramzi Leyh-Bannurah, Markus Graefen, Hartwig Huland, Derya Tilki, Georg Salomon
PURPOSE: To validate current eligibility criteria for focal therapy (FT) in prostate cancer men undergoing radical prostatectomy (RP) and to assess the role of magnetic resonance imaging (MRI). METHODS: Retrospective analysis of 217 RP patients (2009-2016) with preoperative MRI (almost all in external institutions) and fulfillment of different FT eligibility criteria: unilateral tumor, clinical tumor stage ≤ cT2a, prostate volume ≤ 60 mL and either biopsy Gleason 3 + 3 or ≤ 3 + 4 and PSA ≤ 10 or ≤ 15 ng/mL...
February 28, 2018: World Journal of Urology
Alison D Sheridan, Sameer K Nath, Sanjay Aneja, Jamil S Syed, Jay Pahade, Mahan Mathur, Preston Sprenkle, Jeffrey C Weinreb, Michael Spektor
OBJECTIVE: The purpose of this study was to determine imaging and clinical features associated with Prostate Imaging Reporting and Data System (PI-RADS) category 5 lesions identified prospectively at multiparametric MRI (mpMRI) that were found benign at MRI-ultrasound fusion targeted biopsy. MATERIALS AND METHODS: Between January 2015 and July 2016, 325 men underwent prostate mpMRI followed by MRI-ultrasound fusion targeted biopsy of 420 lesions prospectively identified and assessed with PI-RADS version 2...
February 28, 2018: AJR. American Journal of Roentgenology
Chunmei Li, Min Chen, Ben Wan, Jingying Yu, Ming Liu, Wei Zhang, Jianye Wang
Background Although several studies have been reported on evaluating the performance of Gaussian and different non-Gaussian diffusion models on prostate cancer, few studies have been reported on the comparison of different models on differential diagnosis for prostate cancer. Purpose To compare the utility of various metrics derived from monoexponential model (MEM), biexponential model (BEM), stretched-exponential model (SEM) based diffusion-weighted imaging (DWI) and diffusion kurtosis imaging (DKI) in the differential diagnosis of prostate cancer...
January 1, 2018: Acta Radiologica
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"